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ABSTRACT
The receptor tyrosine kinase ERBB2 interacts with HSP90 and is overexpressed 
in aggressive breast cancers. Therapeutic HSP90 inhibitors, i.e. Geldanamycin (GA), 
target ERBB2 to degradation. We have previously shown that HSP90 is responsible 
for the missorting of recycling ERBB2 to degradation compartments. In this study, 
we used biochemical, immunofluorescence and electron microscopy techniques 
to demonstrate that in SKBR3 human breast cancer cells, GA strongly induces 
polyubiquitination and internalization of the full-length p185-ERBB2, and promotes 
its cleavage, with the formation of a p116-ERBB2 form in EEA1-positive endosomes 
(EE). p116-ERBB2 corresponds to a non-ubiquitinated, signaling-impaired, membrane-
bound fragment, which is readily sorted to lysosomes and degraded. To define the 
sequence of events leading to p116-ERBB2 degradation, we first blocked the EE 
maturation/trafficking to late endosomes/lysosomes with wortmannin, and found an 
increase in GA-dependent formation of p116-ERBB2; we then inhibited the proteasome 
activity with MG-132 or lactacystin, and observed an efficient block of p185-ERBB2 
cleavage, and its accumulation in EE, suggesting that p185-ERBB2 polyubiquitination 
is necessary for proteasome-dependent p116-ERBB2 generation occurring in EE. As 
polyubiquitination has also been implicated in autophagy-mediated degradation 
of ERBB2 under different experimental conditions, we exploited this possibility 
and demonstrate that GA strongly inhibits early autophagy, and reduces the levels 
of the autophagy markers atg5-12 and LC3-II, irrespective of GA-induced ERBB2 
polyubiquitination, ruling out a GA-dependent autophagic degradation of ERBB2. In 
conclusion, we propose that HSP90 inhibition fosters ERBB2 polyubiquitination and 
proteasome-dependent generation of a non-ubiquitinated and inactive p116-ERBB2 
form in EE, which is trafficked from altered EE to lysosomes.
INTRODUCTION
ERBB2 is a member of the epidermal growth factor 
(EGF) receptor (ERBB1) family and is chaperoned by 
HSP90; unlike the other ErbB members (ERBB1, ERBB3 
and ERBB4), ERBB2 has no soluble ligands. Upon 
activation ErbB receptors homo- or hererodimerize and 
ERBB2 is the preferred dimerization partner, constituting 
a potent signaling module [1–3]. In normal epithelial 
cells, dimerized ErbB receptors activate AKT and ERK-
dependent pathways that govern cell proliferation and 
survival [3]. ERBB2 is amplified and overexpressed 
in 20% to 30% of human breast cancers, and it is often 
associated with aggressive disease and poor prognosis 
[4]. The oncogenic potential of ERBB2 is also linked 
to preferential recycling and to poor endocytic rate and 
traffic to lysosomes, compared to other members of the 
EGFR family [5]. Although the molecular mechanisms 
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protecting ERBB2 from downregulation are not yet 
sufficiently explored, the hyper-stability of ERBB2 at the 
plasma membrane of overexpressing cells appears to be in 
part ensured by the interaction with the HSP90 chaperone 
[6–9], accompanied by lack of specific endocytic motifs in 
the ERBB2 sequence [10–12].
Targeted therapy based on humanized antibodies to 
ERBB2, i.e. trastuzumab (TZ, Herceptin®), the recently 
FDA-approved antibody-drug conjugate (ADCs) TZ-
TDM1 (Kadcyla®, Genetech, San Francisco), or antibody-
nanoparticles conjugates (ANPs), are under intense clinical 
investigations, in association with HSP90 inhibitors 
[13]. Indeed, the Geldanamycin (GA) analog 17-AAG 
combined with TZ and TZ-TDM1 showed clinical efficacy 
in ERBB2+ breast cancers reporting tumor progression 
when treated with TZ alone [14–18], suggesting that it may 
represent an effective strategy to overcome, or prevent 
drug resistance. In particular, HSP90 inhibition facilitated 
the intracellular delivery of TZ-conjugated nanoparticles 
(ANPs), carrying the chemotherapeutic drug doxorubicin, 
into ERBB2+ breast cancer cells, resulting in improved 
antitumor activity [18].
GA impairs the binding of ADP/ATP to HSP90 
and it is widely utilized in in vitro studies to disrupt 
ERBB2 association with HSP90 [17, 19]. Indeed, HSP90 
inhibitors, including GA, down-regulate ERBB2 very 
efficiently in several breast cancer cell lines [15, 20–28]. 
However, the exact mechanism whereby GA induces 
ERBB2 degradation is not completely understood. Early 
studies showed that GA potentiates ERBB2 cleavage in 
NIH3T3 cells that express the chimeric EGF receptor 
containing the ERBB2 cytoplasmic domain (EGFR/ErbB-
2CD), originating a trans-membrane fragment of about 
135kDa [29, 30]. Whether ERBB2 fragment/s are formed 
in ERBB2 overexpressing breast cancer cells, the nature 
of the protease/s involved, the cell site of the cleavage, 
and the possible intracellular fate of this/these fragment/s, 
remain unclear.
Recent studies focusing on ERBB2 internalization/
trafficking showed that ERBB2 overexpression exerts 
a negative control on clathrin-coated pit formation 
[31], and on EGF-induced clathrin-coated pits [32, 33]. 
However, GA treatment has been reported to promote 
ERBB2 internalization through a clathrin- and a dynamin-
dependent pathway [31, 34–36]. Moreover, GA is 
responsible for the missorting of the internalized ERBB2, 
from recycling to degradative compartments [31, 34]. 
Therefore, it was no surprise that GA-mediated inhibition 
of HSP90 was also able to trigger the recruitment of the 
ubiquitin ligase CHIP and/or c-cbl and to induce rapid 
ubiquitination of ERBB2 [7, 23, 37].
However, to make the story more complex, the 
polyubiquitination of ERBB2 was proposed to either 
induce proteasomal degradation of ERBB2 [38], to enable 
internalization and lysosome degradation [39], or to 
promote a selective autophagy of ERBB2 in breast cancer 
cells [6]. The exact role of the proteasome in GA-mediated 
ERBB2 down-regulation represents a further enigmatic 
issue. It has been described that the proteasome activity is 
required for the initial internalization step or, in contrast, 
for ERBB2 trafficking from early to late/lysosome 
compartments. These discrepancies might depend on 
different experimental settings and/or off-targets effects 
of proteasome inhibitors [35, 36, 38].
In this work, we sought to clarify whether GA induces 
ERBB2 cleavage in SKBR3 cells, and to characterize 
the ERBB2 cleaved isoform/s in terms of downstream 
signaling, protease/s involved and final intracellular 
fate. We show that GA induces polyubiquitination of the 
full length p185-ERBB2, and potentiates the formation 
of a p116-ERBB2 non-ubiquitinated and signaling 
impaired fragment in altered early endosomes (EE), 
which is trafficked via multivescicular bodies (MVBs), 
and degraded in lysosomes. Furthermore, we report that 
proteasome activity is required for the generation of the 
p116 cleaved ERBB2 in EE. Lastly, we also show that 
early autophagy is strongly inhibited upon GA treatment, 
therefore ruling out this catabolic pathway for the ERBB2 
degradation in HSP90 inhibited cells. Altogether, our 
data support that HSP90 inhibition triggers multiple and 
coordinated events that orchestrate efficient ERBB2 down-
regulation.
RESULTS
ERBB2 is preferentially internalized as  
full-length receptor
It has been reported that ERBB2 is internalized and 
degraded in lysosomes upon HSP90 inhibition [31, 33, 34]. 
To confirm this finding in our cell model system, we 
performed immunofluorescence studies to localize ERBB2 
within the endosomal compartment. The data showed very 
poor or even absent co-localization between ERBB2 and 
lysosome LAMP-1 compartments upon GA treatment, as 
most of the internalized ERBB2 co-localized with TfR 
(Supplementary Figure S1). Moreover, since ERBB2 
did not co-localize with the recycling endosome marker 
Rab11, we confirm our previous findings [31] suggesting 
that upon HSP90 inhibition the receptor does not follow 
its normal recycling fate. However, by using the modified 
immunoperoxidase DAB/AA method and Trastuzumab-
HRP (TZ-HRP) as probe to detect ERBB2, we observed 
the localization of this receptor also in multivescicular 
bodies (MVBs) upon GA treatment (Supplementary 
Figure S2A and S2B) [31].
These data can be either explained by a rapid 
ERBB2 degradation within lysosomes, or by an inefficient 
routing of the receptor to these compartments. However, 
as it has also been showed that ERBB2 undergoes a 
proteolytic cleavage upon GA treatment [2, 29, 30, 37], 
a third possible scenario could be that, upon ERBB2 
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cleavage, the receptor fragments follow a lysosome-
independent degradation fate.
To discriminate among these scenarios, we first 
evaluated whether GA promotes ERBB2 cleavage in 
SKBR3 cells. By western blot analysis we observed that 
GA potentiates ERBB2 cleavage, leading to a 116 kDa 
trans-membrane N-terminal fragment, detectable with 
the Ab-20 antibody (Figure 1) (Table 1), recognizing the 
extracellular domain of ERBB2, but not with the C-18 
antibody, recognizing the ERBB2 intracellular C-terminal 
domain (Figure 1).
We next investigated whether ERBB2 cleavage 
events are necessary for the receptor internalization, and 
performed a double immunofluorescence analysis in GA-
Figure 1: GA potentiates p116 ErbB2 cleavage which is enhanced when EE are inhibited with wortmannin. A. SKBR3 
cells were untreated or pre-treated with the PI3K inhibitor wortmannin (WT) (100nM), and/or the proteasome inhibitors MG132 (10μM) 
for 30 minutes at 37°C and GA was added for 1.5 hours at 37°C in the presence or absence of the inhibitors. Cell lysates were subjected to 
immunoblot analysis with antibodies to ERBB2 (Ab-20), ERBB2 (C-18) and p-AKT. GAPDH was used as loading control. Both a short 
and a long exposure (exp.) of the same blot are shown to better highlight the ERBB2 cleaved isoform, as indicated. The blot shown is 
representative of three-independent experiments. On the left side of each panel the migration of protein molecular mass standards expressed 
in kDa is shown. B. Histogram shows the ratio of p116 ERBB2 and p185 ERBB2. Bars represent the means ± SEM of three independent 
experiments (**p<0.05).
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treated and untreated cells, using 9G6 and Ab-1 antibodies. 
Both antibodies co-localized within EEA1-labeled EE 
(Figure 2A), suggesting that ERBB2 is preferentially 
internalized and routed to EE as a full-length receptor. Of 
note, the EEA1 compartment in GA treated cells displayed 
a different morphology compared to untreated cells, as in 
the former EE appeared irregular in shape, in accordance 
to the ultrastructure alterations of EE and MVBs described 
in GA treated cells [31, 34], and significantly increased in 
size (0.78μm vs 0.47μm in controls), whereas untreated 
cells displayed a rather round shape, with a peripheral 
labeling (Supplementary Figure S3).
GA-induced ERBB2 cleavage occurs in early 
endosomes
As ERBB2 reaches EE uncleaved, upon GA 
treatment, we wanted to further investigate whether the 
GA-induced ERBB2 cleavage occurred within the altered 
EE compartment, or at later compartments. To this aim we 
took advantage of wortmannin (WT), a potent inhibitor of 
PI3K activity, which is known to dissociate EEA1 from 
EE, thus impairing fusion/trafficking and the maturation 
events involving these compartments [40, 41]. SKBR3 
cells were pre-treated with WT (100nM), for 30 minutes 
at 37°C and then treated with GA. The effectiveness of 
the WT treatment was confirmed by the disappearance of 
the phospho-AKT (p-AKT) signal, the major downstream 
signaling readout of ERBB2, in immunoblot analysis, 
whose phosphorylation depends on PI3K activity, in all 
the conditions of WT treatment, irrespective of ERBB2 
cleavage (Figure 1).
By immunofluorescence analysis, we localized 
ERBB2 using both the 9G6 antibody, directed to the 
extracellular domain, and the Ab-1 antibody, to the 
intracellular domain (Table 1). In GA treated cells we 
calculated the percentage of colocalization of internalized 
ERBB2. The overlapping signal of the two antibodies was 
80%, meaning that the majority of ERBB2 is internalized 
as full-length p185 isoform (Supplementary Figure S4). 
In cells treated with GA and WT, both ERBB2 isoforms 
p116 (9G6 staining alone), and p185 (9G6 and Ab-1 
staining overlapping) were present within EEA1-enlarged 
compartments, whereas only a faint plasma membrane 
labeling was detected (Figure 2B). Supplementary Figure 
S5 shows that the antibody 9G6 specifically recognized the 
p116 ERBB2 isoform under the experimental conditions 
used to perform immunofluorescence analysis. Notably, 
no ERBB2 staining co-localized with LAMP-1 in cells 
treated with GA and WT (Figure 2B), at variance to the 
mild localization observed in cells treated with GA in the 
absence of WT (Supplementary Figure S1), suggesting 
that ERBB2 trafficking was blocked in EE. These results 
support the hypothesis that ERBB2 cleavage occurs in 
EE. To further support this hypothesis, we performed 
western blot analysis of cells treated or untreated with 
GA, in the presence or in the absence of WT. By revealing 
ERBB2 using either the Ab-20, or the C-18 antibodies, 
we observed no differences in the ERBB2 levels in GA 
untreated cells, both in the presence or in the absence of 
WT (Figure 1), as expected. On the contrary, the presence 
of GA promoted the formation of the p116-ERBB2 that 
was higher in the presence of both GA and WT. These 
data suggest that impairment of the EE maturation into 
late endosomes, by WT, allows accumulation of the 
p116 fragment in the EE compartment (Figure 1 and 
2B), supporting a model in which GA promotes ERBB2 
internalization into EE, followed by cleavage into a p116 
fragment.
Proteasome activity is required for ERBB2 
cleavage in EE
Contrasting results have been reported with 
respect to proteasome requirement for ERBB2 cleavage, 
endocytosis and degradation under GA inhibition [36, 
38]. To test whether the proteasome is involved in the 
generation of the p116-ERBB2 isoform, we performed 
experiments in the presence of two proteasome inhibitors, 
i.e. MG-132 and lactacystin (LC). MG132 is a potent 
reversible inhibitor of chymotrypsin-like (CT-L) activity 
and of the cysteine protease calpain-1, whereas LC is 
an irreversible and efficient inhibitor of proteasome 
CT-L activity, but has no activity on cysteine and serine 
proteases. SKBR3 cells pre-incubated with 10μM LC, 
or 10μM MG132, for 30 minutes at 37°C, were treated 
with 20μM GA in the presence of LC or MG132, for 
further 2 hours at 37°C. Under these conditions, we 
Table 1: anti-ERBB2 antibodies used in this study
Antibody Epitopes Use in this study Suppliers
9G6 N-terminal IF Santa Cruz Biotechnology
Ab-20 N-terminal WB Thermo
Trastuzumab N-terminal IP, IF, EM Genentech-Roche
Ab-1 C-terminal IF Thermo
C-18 C-terminal WB Santa Cruz Biotechnology
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observed that proteasome inhibition efficiently prevents 
the GA-dependent ERBB2 cleavage (Figure 3A). Double 
immunofluorescence analysis, using the 9G6 and the Ab-1 
antibodies, showed that in the presence of GA and MG132 
the uncleaved ERBB2 is mainly localized in enlarged 
intracellular compartments, and on the plasma membrane 
(Figure 3B and Supplementary Figure S6A). However, if 
GA treatment was combined with MG132 and WT, the 
plasma membrane labeling disappears and the uncleaved 
ERBB2 remains localized in even larger intracellular 
compartments (Supplementary Figure S6B), supporting 
the hypothesis for a proteasome role in ERBB2 cleavage 
in the EE. To further characterize these compartments 
we performed an immunoelectron microscopy analysis 
on cryosections, and found that while in GA treated cells 
ERBB2 localizes within MVBs, in the presence of GA 
and MG132, the receptor is localized in EE/recycling 
compartments, and at the cell surface (Figure 4).
Collectively, these data strongly suggest that 
proteasome activity is required for ERBB2 cleavage 
within EE, and suggest that this event is necessary for 
the further trafficking to late/lysosomal compartments. 
Figure 2: The full-lenght ERBB2 is trafficked to EEA1-positive compartments upon GA. A. Internalized ERBB2 in GA-
treated SKBR3 cells for 2 hours is detected by confocal immunofluorescence with antibodies against the extracellular (9G6, green signal) 
and intracellular (Ab-1, red signal) domains. Colocalization is shown as merged yellow signal (upper panel). The lower panel shows a 
magnified field of the areas boxed in the panels above. Arrows show colocalized signals. SKBR3 cells treated with GA for 2 hours and 
ERBB2 localization (9G6 and Ab-1, green signal) with endogenous EEA1 (red signal) is shown. Insets show signal colocalization at a 
higher magnification. Scale bars: 20μM. 
(Continued )
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Of note, when LC was used instead of MG132 to inhibit 
the proteasome activity, we obtained similar results (not 
shown).
MG132 has an inhibitory activity on calpain-1, 
and calpain-1 associates to HSP90 and appears to be 
implicated in constitutive ERBB2 digestion in in vitro 
experiments [42, 43]. Therefore, we wanted to rule-out the 
role of this non-lysosomal cysteine protease in the GA-
dependent generation of p116-ERBB2. Taking advantage 
of the specific calpain inhibitor-1 (ALLN), which 
reversibly blocks calpain-1 activity at concentrations 
ranging between 1-2μM. We pre-treated SKBr3 cells with 
2μM ALLN for 30 minutes at 37°C and subsequently 
added 20μM GA for 2 hours at 37°C in the presence of 
the inhibitor, and analyzed the cells by western blot and 
immunofluorescence. The results show that ALLN did 
not prevent either ERBB2 cleavage or endocytosis in the 
presence of GA (Supplementary Figure S7). Accordingly, 
activation of calpain-1 with 1μM Ca2+ ionophore did 
not induce fragmentation of ERBB2 (Supplementary 
Figure S7). These results rule out the involvement 
of calpain-1 in GA-dependent ERBB2 cleavage and 
endocytosis and suggest that ERBB2 cleavage depends on 
the activity of the proteasome.
ERBB2 is polyubiquitinated in GA-treated cells
As proteasome inhibitors impaired the formation 
of p116-ERBB2, we sought to confirm in our model 
system the reported GA-dependent polyubiquitination 
of ERBB2 [23]. We immunoprecipitated ERBB2 from 
GA treated and control untreated cells, using TZ, and 
Figure 2 (Continued): B. Effects of GA in combination with WT on ERBB2 localization detected by confocal immunofluorescence. 
Images show intracellular and plasma membrane localization of ERBB2 detected with anti-ERBB2 (green signal, 9G6) and with anti-
ERBB2 antibody (red signal, Ab-1). In addition, co-localization of internalized ERBB2 (9G6) with the EE marker EEA1 and the lysosomal 
marker LAMP1 in GA+WT treated cells is shown. Colocalization is shown as yellow signal in the merged images. Size bar: 20μM.
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revealed polyubiquitination by western blot analysis, 
using a specific antibody recognizing polyubiquitin chains. 
As expected [23, 44], HSP90 inhibition promotes the 
polyubiquitination of ERBB2 (Figure 5), but not of TfR 
immunoprecipitated with a specific antibody, used as a 
negative control (Supplementary Figure S8). In particular, 
in the TZ immunoprecipitates, the anti-polyubiquitin 
antibody recognized a band migrating slower than 
185kDa, confirming the polyubiquitination of the full-
length ERBB2 form (Figure 5). However, challenging the 
same blot with Ab-20, revealed only the non-ubiquitinated 
ERBB2 isoforms (Figure 5), suggesting that only a minor 
amount of ERBB2 is polyubiquitinated and likely rapidly 
degraded. In addition, to determine whether proteasome 
inhibition affects the levels of polyubiquitinated ERBB2, 
we immunoprecipitated ERBB2 from cells co-treated 
with GA and MG-132 and with GA and LC, using TZ, 
and revealed the levels of polyubiquitination by western 
blot analysis (Figure 5), and found that MG-132 and 
LC increased the abundance of polyubiquitinated 
ERBB2 in the presence of GA, with LC having a more 
robust effect than MG-132. These results confirm that 
full-length ERBB2 is polyubiquitinated under GA and 
that proteasome inhibition induces accumulation of 
polyubiquitinated ERBB2.
Degradation of the p116-ERBB2 fragment 
occurs in the endosome/lysosome compartments
Our results indicate so far that, upon GA treatment, 
ERBB2 is cleaved in EE giving origin to a p116 protein, 
in a proteasome-dependent manner. We next asked 
whether the degradation of p116-ERBB2 occurs in 
the late endosome/lysosome, or in EE compartments. 
To answer this question, we localized ERBB2 by 
immunofluorescence in GA treated cells, in the presence 
or in the absence of the lysosomal inhibitor bafilomycin 
A1 (Baf), a specific inhibitor of the vacuolar H+ ATPase 
(V-ATPase). The co-localization between endogenous 
ERBB2 and LAMP-1 (Figure 6A) increased in the 
presence of Baf, compared to control cells (Figure 6B). 
These results support the conclusion that ERBB2 cleaved 
Figure 3: Proteasome is responsible for the generation of p116-ERBB2 under GA. A. SKBR3 cells were pre-treated with the 
proteasome inhibitors MG132 (10μM) and lactacystin (LC) (10μM) for 30 minutes at 37°C and GA was added for 1.5 hours at 37°C in the 
presence of the inhibitors. Note that p116-ERBB2 is detectable only after GA treatment, and that ERBB2 cleavage is completely prevented 
when the proteasome activity is inhibited (Ab-20, upper panel). In the middle panel, p185-ERBB2 was detected with C-18 antibody. 
Note that, in both GA+LC and GA+MG132 treated cells ERBB2 degradation of the p185 isoform, as detected by C-18 Ab, is inhibited if 
compared to GA treated cells. GAPDH was used as loading control (lower panel). The blot shown is representative of three-independent 
experiments and the left four samples belong to a different experiment respect to the right four samples. On the left side of each panel the 
migration of protein molecular mass standards expressed in kDa is shown.
(Continued )
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in EE is eventually rapidly degraded in lysosomes, so that 
it becomes promptly detectable only when their activity 
is inhibited.
These results were confirmed by biochemical 
analysis. SKBR3 cells were incubated with either one of 
two lysosome inhibitors, i.e. 200nM Baf (Figure 7), or 
200nM cloroquine (CQ)(Supplementary Figure S9), in 
the presence or in the absence of GA. Indeed, the p116 
fragment was less abundant (Figure 7) in cells treated 
with GA, whereas it was greatly accumulated when the 
degradative activity of lysosomes was inhibited by Baf 
(Figure 7). Furthermore, the levels of p-AKT, were almost 
abolished upon GA treatment, either in the presence or in 
the absence of Baf (Figure 7). This further supports the 
conclusion that the cleavage leading to the formation of 
the signaling-impaired p116-ERBB2 fragment, lacking the 
carboxy-terminal kinase domain, occurred in EE, before 
the receptor reached the degradation sites. This conclusion 
was also in agreement with the observation that Baf failed 
to inhibit ERBB2 cleavage (Figure 7).
We have previously reported that GA treatment 
re-routes recycling cargoes (i.e. ERBB2 and TfR) from 
early/recycling compartments to late MVBs [31]. These 
events involve the reshaping of endocytic compartments. 
We now find that ERBB2 trafficking to late endosomes/
lysosome compartments upon GA treatment follows a 
proteasome cleavage of the receptor in a 116 fragment, in 
the EE. To better characterize the endocytic compartments 
Figure 3 (Continued): B. ERBB2 localization upon proteasomal inhibition with MG132. Representative confocal images of ERBB2 
intracellular localization obtained from untreated or GA-treated SKBR3 cells in the presence or absence of 10μM MG132. The green signal 
shows ERBB2 extracellular domain (9G6), the red signal shows ERBB2 intracellular domain (Ab-1). Colocalization is shown as yellow 
signal. Full-length ERBB2 (yellow signal) is detectable at the intracellular level in both GA-treated and co-treated with MG132. Notably, 
enlarged ERBB2-positive endosomal structures and plasma membrane staining are visible in GA+MG132 co-treated cells. Images are 
representative of three independent experiments. Scale bars: 20 μm.
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involved ERBB2 trafficking in cells treated by GA in 
the presence of Baf, we took advantage of the modified 
immunoperoxidase DAB/AA method we reported earlier 
[45], and used TZ-HRP to track ERBB2. Briefly, SKBR3 
cells were pre-treated with 20μM GA for 20 min at 37°C, 
transferred on ice, and labeled for 15 minutes with TZ-
HRP. After washing out the excess of TZ-HRP, cells were 
incubated for 2 hours at 37°C with or without GA, in 
the presence or in the absence of Baf. By morphology, 
we identified four classes of ERBB2-positive endocytic 
structures in GA and GA+Baf treated cells: endosomes 
(~250nm), small multivesicular bodies (sMVBs) 
(~100nm, 1-2 intraluminal vesicles), MVBs (~300nm, 
>10 intraluminal vesicles), and an unconventional 
compartment that we named bafilomycin-derived vesicles 
(BDVs, ~300nm) (Supplementary Figure S2A). By 
morphometry, we quantitated the surface occupancy of 
each of these compartments in the different treatment 
conditions (Supplementary Figure S2B). The data 
confirmed the ERBB2 routing to MVBs, as we previously 
described [31], and revealed defects in MVB maturation/
fusion in the presence of GA+Baf, represented by MVB 
smaller in size and often clustered in discrete regions of 
the cytoplasm (small MVBs) [46], and the appearance of 
BDVs, electron-lucent endosomal structures containing a 
weak TZ-HRP labeling, that represented the most frequent 
phenotype.
Since TZ has been shown to modulate intracellular 
signaling pathways [3, 47], we wanted to rule out the 
possibility that the TZ used to track ERBB2 in our 
experiments could interfere with the GA-induced ERBB2 
cleavage, trafficking, degradation and downstream 
signaling. By western blot analysis we found that 
treatment with TZ alone does not generate the 116kD 
cleaved ERBB2 fragment, and does not interfere with the 
cleavage induced by GA. Accordingly, lack of p-AKT 
phosphorylation was also observed in GA+TZ treated cells 
(Supplementary Figure S10A). Moreover, we checked 
whether TZ was interfering with the GA-induced ERBB2 
trafficking, by immunofluorescence. The antibody TZ-
Figure 4: Ultrastructural localization of ERBB2 in SKBR3 cells treated with GA and proteasome inhibitors. Cryosections 
of SKBR3 cells were labeled with antibodies against ERBB2 (9G6), followed by protein A-coated (15nm) colloidal gold (black dots). 
The labeling shows that ERBB2 localized to the highly ruffled plasma membrane in untreated cells A., and mainly in multivescicular 
bodies (MVBs) in GA-treated cells B. Cells treated with 10μM MG132 show plasma membrane localization of ERBB2, as in untreated 
cells C. Cells co-treated with GA and MG132 show intracellular localization of ERBB2 in morphologically resembling early/recycling 
endosomes (D).
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Alexa488 was allowed to internalize for 2 hours at 37°C 
in cells treated or untreated with GA, in the presence or 
the absence of Baf. Co-localization studies with LAMP-1 
revealed no differences in ERBB2 trafficking to lysosomes 
using TZ-Alexa488 compared with endogenous ERBB2 
trafficking, supporting that, in the presence of GA, TZ 
is affecting neither ERBB2 cleavage nor its trafficking 
(Supplementary Figure S10B-S10C).
Autophagy is not a relevant mechanism for  
GA-mediated ERBB2 down-regulation
Recent work demonstrated that certain conditions 
that promote ERBB2 polyubiquitination may lead to 
the receptor degradation by autophagy [6]. Therefore, 
we were prompted to evaluate whether autophagy 
could be a possible degradation modality in GA treated 
cells. By measuring LC3-II levels as a functional 
reporter of autophagy [48, 49], we first, transiently 
transfected SKBR3 with GFP-LC3 for 18 hours and 
scored by immunofluorescence the number of LC3 
dots under different treatment conditions. We found 
that GA treatment reduced the number of LC3-II dots 
within cells (Figure 8A-8C), suggesting that HSP90 
inhibition suppresses autophagy in contrast to previous 
studies in different experimental settings [50, 51]. To 
assess whether the LC3-II reduction resulted from 
either decreased autophagosomes synthesis, or from 
an increased degradation, we evaluated the autophagic 
flux in the presence of Baf, that is known to block 
autophagosome degradation [49, 52]. SKBR3 cells 
treated or untreated with GA, in the presence or the 
absence of Baf, were analyzed by western blot for LC3I-
II levels (Figure 8D). LC3-II levels were lower in the 
conditions without Baf, compared to treatments in the 
presence of the inhibitor, confirming that GA reduced 
LC3-II levels by interfering with autophagosome 
synthesis. As a second approach, we took advantage 
of the observation that the activity of the conserved 
Atg12-Atg5-Atg16 complex is essential for initial 
Figure 5: GA induces polyubiquitination of p185-ERBB2. SKBR3 cells were pre-treated with the proteasome inhibitors MG132 
(10μM) and lactacystin (LC) (10μM) for 30 minutes at 37°C and GA was added for 1.5 hours at 37°C in the presence or absence of 
the inhibitors. Cells were then lysed as described under the material and method section. The cell lysates were immunoprecipitated 
with trastuzumab (TZ) in order to detect ERBB2. Immunoprecipitates were resolved by SDS/PAGE and immunoblotted with an anti-
polyubiquitin (upper panel), and an anti-ERBB2 (Ab-20) antibody (lower panel) are shown. On the left side of the panels the migration of 
protein molecular mass standards expressed in kDa is shown.
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autophagosome biogenesis [53]. Therefore, by western 
blotting we analyzed the levels of Atg5-Atg12 complex 
in cells treated or not with GA, in the presence or the 
absence of Baf (Figure 8C). As expected, GA down-
regulates the Atg5-Agt12 complex, further confirming its 
role in impairing autophagosome biogenesis. Of note, we 
could not detect ERBB2-positive autophagic structures in 
the EM analysis in cells treated with GA, irrespective of 
the presence or not of Baf (Supplementary Figure S2A). 
Collectively, these results suggest that early autophagy 
is strongly inhibited in GA-treated cells, excluding this 
catabolic pathway for ERBB2 degradation.
Figure 6: The N-terminal ERBB2 fragment is readily delivered to lysosomes. A. SKBR3 cells were pre-incubated with 
200nM BafilomycinA1 (Baf) for 30 minutes at 37°C and then with 20μM GA, Baf and GA+Baf for 1.5 hours at 37°C. Cells were fixed 
and labelled for ERBB2 (9G6, green signal) and the lysosomal marker LAMP1 (red signal). Representative confocal microscopy images 
are shown. Note that in the case of GA-treated cells, only few ERBB2 is found inside lysosomes, whereas the colocalization is greatly 
increased when Baf was added in co-treatment with GA. Insets on the right side of each image show at higher magnification the boxed 
area. Size bars: 10μM. B. Pixel quantification of ERBB2-LAMP1 colocalization per cell (n=3, 50 cells analyzed each experiment) in GA 
versus GA+Baf treated cells is depicted as box plot. The bottom and the top of each box are the first and third quartile, while the line 
inside the box represents the median (second quartile). The ends of the whiskers represent the minimum and the maximum data value. A 
significant increase (p=0.038) of ERBB2 colocalization with LAMP1 is shown when lysosomal activity was inhibited by Baf. Images and 
quantification are representative of three independent experiments.
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DISCUSSION
Overexpression of ERBB2 in breast cancers 
correlates with a poor prognosis due to enhanced 
metastatic potential and resistance to chemotherapy. 
For these reasons, many efforts have been spent in the 
development of therapeutic antibodies (i.e. TZ) [54, 
55] and HSP90 inhibitors that have shown to be able 
to stimulate ERBB2 endocytosis and termination of 
downstream signaling. Since the discovery of the natural 
product GA in 1970, the portfolio of HSP90 inhibitors has 
been greatly expanded and includes multiple drug classes, 
with different modes of action, that are undergoing clinical 
evaluation [14, 17]. ERBB2 is “addicted” to HSP90 and is 
very sensitive to HSP90 inhibition in pre-clinical models. 
In the clinic, the efficacy of this class of therapeutic agents 
has been relatively limited, with promising responses 
mainly observed in ERBB2+ breast and lung cancers. 
Notably, the GA analog 17-AAG combined with TZ 
showed increased clinical efficacy in ERBB2+ breast 
cancer patients that become resistant to TZ, highlighting 
HSP90 inhibitors as effective agents to overcome or 
prevent drug resistance [56]. At the present, the knowledge 
of the basic cellular and molecular mechanisms underlying 
ERBB2 down-regulation under HSP90 inhibition is still 
not completely clear.
In particular, endocytic down-regulation is a 
recurrent theme in ERBB cancer biology. Indeed, ERBB2 
has been considered either to be endocytosis-resistant, or 
a fast recycling receptor confined to the plasma membrane 
[11, 34].
The objectives of this study were to determine 
the sequence of events leading to ERBB2 degradation 
upon HSP90 inhibition, to understand the mechanism 
of action of potentially useful anti-cancer drugs, and to 
better understand the biology of the role of HSP90 in the 
homeostasis of ERBB2.
Our data suggest a model for ERBB2 degradation 
induced by GA, which can be described as a four steps 
process: first, ERBB2 polyubiquitation of the full length 
Figure 7: p116-ERBB2 isoform is signaling impaired and degraded in lysosomes. SKBR3 cells were untreated or treated 
with 20μM GA, 200nM BafilomycinA1 (Baf) alone or in combination for 2 hours at 37°C. The total p185-ERBB2, the GA-induced p116-
ERBB2, p-AKT and TfR protein levels were assessed by Western blot using Abs recognizing the extracellular domain of ERBB2 (Ab-20), 
p-AKT and TfR. Calnexin was used as loading control. On the left side of the blot the migration of protein molecular mass standards 
expressed in kDa is shown.
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Figure 8: GA inhibits early autophagy. A. SKBR3 transiently transfected with GFP-LC3 for 18 hours and then treated with GA, 
BafilomycinA1 (Baf) and GA+Baf for 2 hours at 37°C (green signal, GFP-LC3; blue signal, DAPI). Representative images are shown from 
two independent experiments. Scale bars: 10μM. Note that in GA-treated cells few GFP-LC3 dots are visible if compared to untreated and 
Baf-treated cells. B. Quantification of the average number of LC3 dots in cells (n=50) shows that GA significantly decreases LC3-positive 
autophagosomes (p=0.035) compared to untreated cells. Accordingly, when Baf was added to inhibit autophagosome/lysosomal fusion, GA 
treatment decreases the number of LC3-positive autophagosomes (p=0.017). C. Quantification of the average size of LC3 dots in SKBR3 
cells (n=3, 50 cells analyzed each experiment). GA significantly decreases LC3-positive autophagosomes size (p=0.001) either alone or in 
co-treatment with Baf. The bottom and the top of each box are the first and third quartile, while the line inside the box represents the median 
(second quartile). The ends of the wiskers represent the minimum and the maximum data value. D. Autophagic flux was assessed by western 
blot analysis in SKBR3 cells treated with GA, Baf and GA+Baf for 2 hours at 37°C in the absence or presence of TZ. Accordingly with 
data presented in (A), LC3-II levels were decreased in the presence of GA. The level of LC3-II is increased in the presence of the lysosomal 
inhibitor Baf because the transit of LC3-II through the autophagic pathway is blocked, but is decreased in GA+Baf treated cells, indicating 
inhibition of early autophagy. TZ does not influence the inhibition of autophagy mediated by GA. E. Protein levels of the early autophagy 
marker atg5-atg12 complex is assessed by western blot analysis in SKBR3 cells treated with GA, Baf and GA+Baf for 2 hours at 37°C. It 
is shown that GA reduces the level of this complex. GAPDH was used as loading control for all the experiments. On the left side of each 
panel the migration of protein molecular mass standards expressed in kDa is shown.
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p185-ERBB2 cytoplasmic tail; second, internalization 
and trafficking of the polyubiquitinated receptor to EE; 
third, the generation of a p116-ERBB2 cleaved fragment, 
by proteasome removal of the ubiquitinated cytoplasmic 
tail from the p185-ERBB2; and fourth, trafficking to late 
endosomes/lysosomes and rapid degradation of the p116-
ERBB2 fragment. In addition, we suggest that the p116/
p185 ERBB2 ratio could be of help in the assessment of 
response to GA derivatives in tumor-derived organoids.
Some of our findings confirm previous studies, in 
particular here we show that GA promotes the generation 
of a p116-ERBB2 signaling impaired fragment in SKBR3 
cells, which overexpress the endogenous ERBB2 due to 
ERBB2 gene amplification. Previous findings reported the 
generation of a 135kDa fragment upon GA treatment [29], 
this discrepancy in fragments mass is likely due to the use 
of an ERBB2/ERBB1 chimeric construct expressed in 
NIH3T3 mouse fibroblasts [29]. In addition, our finding 
of ERBB2 polyubiquitination and cleavage induced by GA 
treatment confirm previous studies [23, 29, 39].
However, here we define for the first time that 
the ERBB2 polyubiquitination occurs on the full-
length p185 receptor, and it is a necessary event for the 
cleavage of ERBB2 cytoplasmic tail, due to proteasome 
activity in EE. These findings reconcile two not mutually 
exclusive hypotheses on the role of polyubiquitination 
in GA-mediated ERBB2 down-regulation. In the first, 
polyubiquitin chains have been suggested to serve as 
endocytic sorting signal, triggering internalization of full-
length ERBB2 from the plasma membrane, as suggested 
by the observation that a tetra-Ub-containing fusion 
protein, ERBB2-Ub4, is constitutively endocytosed, and 
not cleaved in the absence of the GA analog 17-AAG 
[39]. In the second hypothesis, polyubiquitination has 
been proposed to represent the molecular signal triggering 
the intracellular cleavage, necessary to sort ERBB2 to 
EE and then multivescicular bodies (MVBs), en route to 
lysosomes [10].
In particular, we provide evidences that cleavage 
of the polyubiquitinated p185-ERBB2 occurs in EE, 
before final degradation of the p116-ERBB2 in the late 
endosome/lysosome compartments. In agreement with 
the original observations by Lerdrup and by Pedersen 
[36, 38], we found p185-ERBB2 associated to EEA1-
positive endosomes, when using antibodies recognizing 
both the extracellular and intracellular regions of ERBB2 
in GA treated cells, strongly suggesting that ERBB2 is 
not cleaved before endocytosis. In addition, impairing 
EE fusion/trafficking with the PI3K inhibitor wortmannin 
(WT) [41] in GA treated cells, leads to an increase in the 
p116-ERBB2 isoform within enlarged EEA1-endosomes, 
and not in LAMP1 lysosomes. It should be noticed that 
both GA analogues and PI3K inhibitors are either under 
development in clinical trials, or already approved. Based 
on our data, it is possible to speculate that the combined 
use of these drugs may turn out to be effective in reducing 
breast cancer cells proliferation/survival in vivo.
Of note, the ERBB2 positive EE observed in GA 
treated cells were morphologically altered, as we have 
previously demonstrated by ultrastructural studies [31].
A further unclear aspect of the GA dependent events 
leading to ERBB2 degradation was the precise role of 
the proteasome for ERBB2 down-regulation, which has 
long been a matter of debate [29, 36, 38]. In this study, 
we show by biochemical analysis that proteasome 
inhibition by MG132, in the presence of GA, dramatically 
impairs the generation of p116-ERBB2 isoform, even 
in cells co-treated with WT, leading to accumulation of 
polyubiquitinated p185-ERBB2. This finding suggests 
that ERBB2 cleavage in the EE and the subsequent 
p116-ERBB2 sorting to late endosomes/lysosomes is 
dependent upon proteasome activity. Of note, under 
GA and proteasome inhibition, we observe an increase 
of ERBB2 at the plasma membrane in a large fraction 
of cells, possibly because of the impaired trafficking 
of the polyubiquitinated p185-ERBB2 to the receptor-
saturated EE. By immunoelectron microscopy we find 
the receptor associated to intraluminal vesicles of MVBs 
upon GA treatment. However, when cells are co-treated 
with the proteasome inhibitor MG132, ERBB2 localizes 
to compartments with EE morphology, containing few 
or no internal vesicles, and with the labeling restricted 
to the outer limiting membrane, a typical feature of 
recycling receptors [57]. These observations provide a 
likely scenario for the sequence of events preluding to the 
ERBB2 missorting from recycling, to degradation in late 
endosomes/lysosomes, that we have previously described 
[31].
Therefore, we believe that the overall GA-induced 
p116 cleavage and subsequent EE/LE trafficking, but not 
its internalization, depends on proteasome activity.
MG132 was reported to also inhibit calpain-1. The 
involvement of calpain-1 in regulation of TZ sensitivity 
and survival pathway by regulating cleavage and activity 
of ERBB2 in breast cancers has been recently investigated 
[42]. In addition, calpain-1 associates with HSP90, in 
which the chaperone appears to restrain its proteolytic 
activity [43]. Based on these findings, we reasoned that 
GA might influence the protease activity of calpain-1 in 
SKBR3 cells. However, we found that specific inhibition 
of calpain-1 with the calpain-1 inhibitor (ALLN) had no 
effect on p116-ERBB2 isoform generation and ERBB2 
internalization in GA-treated cells. Therefore, we 
concluded that the observed effects of MG132 on ERBB2 
cleavage were not dependent from calpain-1. Lastly, 
we asked whether the degradation of the ERBB2 p116 
fragment occurred in the lysosomal compartments. Our 
biochemical and immunofluorescence data showed that 
the p116 isoform was greatly accumulated in lysosomes 
when their activity was inhibited with bafilomycin A1, 
confirming that its final fate is the lysosomal degradation.
In parallel to endocytosis, autophagy represents 
another major pathway for protein degradation sharing with 
endocytosis part of the molecular machinery [58]. In cancer 
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cells, autophagy has dual roles, acting as both a tumor 
suppressor by preventing the accumulation of damaged 
proteins and organelles and as a mechanism of cell survival 
that can promote the growth of established tumors [59]. 
Recently, a cross-talk between polyubiquitination of 
surface receptors and autophagy-mediated degradation 
has been demonstrated [60]. In breast cancer cells, when 
the p130Cas adaptor protein is depleted, ERBB2 becomes 
ubiquitinated by c-cbl and degraded via autophagy [6]. 
In our study, we found that GA strongly impaired early 
autophagy, as shown by the decrease of LC3-II and 
Atg5-12 complex levels, highlighting GA as a potent 
early autophagy inhibitor in breast cancer SKBR3 cells. 
These results indicate that HSP90 regulates early steps of 
autophagy as part of its anti-cancer activity, but it is likely 
not involved in degradation of polyubiquitinated ERBB2.
In conclusion, our study shows that as a result 
of the coordinated activities of ubiquitin/proteasome 
and endocytic pathways, the full-length ERBB2 is 
polyubiquitinated, internalized and sorted to EE, cleaved 
into a p116 isoform, en route to degradation in lysosomes. 
GA treatment potentiates these events and in addition acts 
as potent early autophagy inhibitor in our experimental 
settings. Together, our findings provide novel insights 
into the role of HSP90 in ERBB2 processing, and of the 
molecular mechanisms underlying HSP90 inhibition in 
SKBR3 breast cancer cells.
MATERIALS AND METHODS
Cell culture
Human breast cancer (SKBR3) overexpressing 
ERBB2 were obtained from ATCC. Cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco, 
Carlsbad, CA, USA) supplemented with 10% heat 
inactivated Fetal Bovine Serum and 2mM glutamine 
(Gibco, Carlsbad, CA, USA) and maintained in 5% CO2. 
Confluent cells were split with Trypsin-EDTA (Gibco, 
Carlsbad, CA, USA) and passaged at an appropriate 
density. SKBR3 cells were transiently transfected with 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) 
and examined 18 hours post-transfection according to 
instructions.
Antibodies and reagents
Antibodies against ERBB2 are listed in Table 1 
along with epitope specificity, applications and suppliers. 
Of note, Trastuzumab (Trastuzumab®, Genentech and 
Roche, South San Francisco, USA) was from the week 
residues of the pharmacy of IST (Istituto Nazionale 
Tumori, Genova, Italy) kindly donated to Carlo Tacchetti 
for research purposes, at a concentration of 21mg/ml.
Rabbit polyclonal anti-EEA1 (H-300) was from 
Santa Cruz. Mouse monoclonal anti-LAMP1 (H4A4) was 
from Hybridoma Bank (Iowa City, Iowa, USA). Rabbit 
polyclonal anti-LAMP1 (L1418) was from Sigma-Aldrich. 
Mouse anti-human Transferrin receptor (clone H68.4) was 
from Invitrogen. Anti-LC3 (clone 5F10) antibody was 
from Nanotools. Rabbit polyclonal anti-ATG5 antibody 
was purchased from Novus Biological. Antibodies to pan-
AKT and p-AKT were purchased from Cell Signaling. 
Anti-polyubiquitin antibody was purchased from 
Millipore (clone FK1). Trastuzumab® conjugation with 
HRP were made using Lightning-Link TM technology 
(Innova Bioscience, Cambridge, UK) according to 
manufacter’s instructions. Trastuzumab conjugation 
with Alexa488 and Alexa555 dye was made with Alexa 
Fluor conjugation kit (A10235, Invitrogen, Carlsbad, CA, 
USA). Geldanamycin, BafilomycinA1, ascorbic acid and 
DAB (3,3-Diaminobenzidine tetrahydrochloride) tablets 
(D5905) were from Sigma-Aldrich (St. Louis, MO, USA). 
Calpain-1 inhibitor (A6185, Sigma-Aldrich) was a gift 
from M. Averna (Dipartimento di Medicina Sperimentale, 
Biochemistry section, Università di Genova). Proteasome 
inhibitors MG-132 (474790) and Lactacystin (416100) 
were purchased from (MERK-Millipore, Darmstadt, 
Germany). Protein A-gold (10-15nm) was purchased from 
Utrecht University, Utrecht, Netherlands.
Electron microscopy
Trastuzumab-HRP internalization assay
SKBR3 cells, cultured on 2-well Lab-Tek chamber 
Slide w/cover permanox (177429, Thermo Fisher 
Scientific, 75 Panorama Creek Drive, Rochester, NY) 
were washed in CO2-independent medium (Gibco, Cat. 
Number 18045070, Carlsbad, CA, USA), incubated in 
CO2-independent medium containing 10 μg/ml TZ-HRP 
on ice for 30 minutes in the presence or in the absence 
of 20μM GA and 200nM BafilomycinA1. After extensive 
wash with cold CO2-independent medium to remove 
unbound TZ-HRP, cells were shifted at 37°C in CO2-
independent medium for 2 hours at 37C, in the presence/
absence of the drug/s. To stop the internalization, cells 
were placed on ice in pre-chilled CO2-independent 
medium, incubated for 20 min at 4°C in freshly prepared 
DAB buffer (1 mg/ml DAB and 0.012% H2O2) with or 
without 50 mM ascorbic acid (AA) in PBS and fixed 
with 2.5% glutaraldehyde (Electron Microscopy Science, 
Hatfield, PA, USA) for 1 h. The cells were subsequently 
processed for standard EM. Cells were embedded in Epon 
epoxy resin (Poly/Bed® 812, Polyscience, Valley Road 
Warrington, PA, USA) and cut parallel to the culture 
substratum. Electron micrographs were taken at CM10 
TEM (Philips, The Netherlands) and analyzed with 
iTEM software (Olympus-SYS, Münster, Germany). 
Quantification of TZ-HRP internalization (±GA, ± 
BafilomycinA1 or both) by EM is represented as histogram 
in which the ratio of the average area occupied by each 
type of ERBB2-positive endocytic structure with the 
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average area of each image was calculated (mean±SEM). 
We defined four classes of ERBB2-positive structures in 
GA+BafilomycinA1 co-treated cells by morphological 
criteria: endosomes (~240nm), small multivesicular bodies 
(sMVBs) (~100nm, 1-2 intraluminal vesicles), MVBs 
(~310nm, >10 intraluminal vesicles), bafilomycin-derived 
vescicles (BDVs) (electron-lucent endosomes, ~300nm). 
We analyzed 30 images for each treatment (magnification 
of 19500x) in two independent experiments.
Immunogold labeling
SKBR3 cells, cultured on 6-cm dishes, were 
washed in CO2-independent medium and incubated in 
CO2-independent medium containing 20μM GA, either 
alone or in the presence of proteasomal inhibitors 10μM 
MG132 and 10μM lactacystin for 2 hours at 37C. Cells 
were then prepared for cryo-immunoEM according to 
the Tokuyasu method. Briefly, cells were fixed in 2% 
paraformaldehyde - 0.2% glutaraldehyde in PBS for 2 
hours at room temperature. Next, cells were gently scraped 
and embedded in 12% gelatin. After overnight Sucrose 
2.3M infusion, small squared blocks were mounted on 
aluminium pins and frozen in liquid nitrogen. Ultrathin 
cryosections of 60nm were cut with Leica UltraCut UCT 
microtome (Leica Microsystems, Wetzlar, Germany) and 
immunolabeled with anti-ERBB2 antibody (9G6, Santa 
Cruz, St Louis, USA). Protein A-gold 15nm was used to 
reveal labeling of ERBB2.
Immunofluorescence
For endocytic assays, TZ-Alexa488 was bound 
to SKBR3 cells at 4°C for 20 minutes before starting 
internalization for 2 hours at 37°C. Cells were than 
processed for immunofluorescence and labeled as 
described. Briefly, cells were fixed in 3% paraformaldheyde 
(PFA) in phosphate-buffered saline (PBS) pH 7.4 and 
then quenced with 30mM NH4Cl. After permeabilization 
with 0.2% saponin, cells were incubated with following 
antibodies. For co-localization studies under lysosomal 
inhibition, endogenous ERBB2 was detected with 
anti-ERBB2 9G6 (extracellular domain) antibody or 
internalized TZ (TZ-Alexa488), in combination with anti-
EEA1 or LAMP-1 antibodies.
For co-localization studies under proteasomal 
inhibition, endogenous ERBB2 was detected with anti-
ERBB2 9G6 (extracellular domain) antibody, used as 
primary antibody in combination with anti-ERBB2 Ab-1 
(intracellular domain). The secondary antibodies were 
incubated for 20 min in 0.2% saponin/PBS: Alexa488 
and Alexa546-conjugated donkey anti-mouse or donkey 
anti-rabbit IgG (Life Tecnhologies) and Alexa488-
cojugated goat anti-human IgG (Molecular Probes). 
The coverslips were mounted using Prolong Gold with 
DAPI anti-fading reagent (Thermo Fisher Scientific). 
Image acquisition was perfomed with an Olympus IX70 
epifluorescence microscope. Images were captured 
under oil with a 63x plan apochromat objective. When 
indicated, optical sections were acquired with TCS-SP2 
AOBS confocal microscope station (Leica Microsystems, 
Wetzlar, Germany) or with an Axio Imager A2m equipped 
with an Apotome module for structured illumination 
epifluorescence (Carl Zeiss, Jena, Germany).
Western blot and IP
SKBR3 whole cell lysates were prepared using 
EB Lysis Buffer (Hepes pH 7.4 20 mM, NaCl 150 
mM, Glycerol 10%, Triton X-100 1%) with protease 
inhibitors cocktail (Roche, Basel, Switzerland) and 
sodium orthovanadate. Petri dishes were scraped to 
collect the whole lysates and incubated on ice for 20 
minutes. Lysates were finally centrifuged for 2 minutes 
at 13200 rpm at 4°C to remove cellular debris. Protein 
cell extracts and SDS Polyacrylamide gel electrophoresis 
(NW04120box, BOLT Bis-Tris plus 4-12%, Invitrogen), 
were performed using standard protocols [61]. Proteins 
were detected with ECL Detection Reagent (Amersham, 
Little Chalfont Buckinghamshire, England). Protein 
quantification was performed using Bradford protein assay 
(BioRad, Hercules, CA, USA). ProteinA-Sepharose CL-
4B (GE Healthcare, Piscataway, NJ, USA) was used for 
IP analysis. Rabbit anti-calnexin (sc-11397, Santa Cruz), 
rabbit anti-GAPDH (#2118, Cell Signaling) were used as 
loading control. Secondary antibodies were horseradish 
peroxidase-conjugated: anti-mouse (Molecular Probes, 
Thermo Fisher Scientific, Waltham, MA, USA), anti-
rabbit (Molecular Probes) and anti-goat (Santa Cruz) 
and the detection of proteins were performed with ECL 
Detection Reagent (GE Healthcare).
Statistical analysis
All parameters measured are presented as mean ± 
SEM and were analyzed with two-tailed Student’s t-test or 
the nonparametric Mann–Whitney U test. P values <0.05 
were considered statistically significant.
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